Quick Answer
BioCorRx Inc. reported R&D Expense of $1.77 million for fiscal year 2025.
BioCorRx Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.77M | +19.3% |
| 2024 | $1.48M | +66.4% |
| 2023 | $891.1K | -38.9% |
| 2022 | $1.46M | -9.1% |
| 2021 | $1.61M | -62.4% |
| 2020 | $4.27M | +279.9% |
| 2019 | $1.13M | +641.3% |
| 2018 | $151.8K | -66.3% |
| 2017 | $450.7K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.00M | +118.3% | +238.4% |
| June 30, 2025 | $296.9K | -44.7% | +83.3% |
| March 31, 2025 | $161.9K | -24.3% | -64.8% |
| September 30, 2024 | $460.1K | +60.3% | -14.2% |
| June 30, 2024 | $536.4K | +125.0% | +150.8% |
| March 31, 2024 | $213.8K | -9.9% | -25.5% |
| September 30, 2023 | $287.0K | -16.2% | +20.4% |
| June 30, 2023 | $238.4K | -37.7% | +0.4% |
- BioCorRx Inc. showed an increase of +19.3% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, BioCorRx Inc.’s r&d expense has grown by 292.5% (from $450.7 thousand to $1.77 million).
- The most recent figure is from BioCorRx Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: